Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Harnessing Regulatory T Cells to Modulate Acute Brain Injury: From Mechanisms to Therapy.

Molecular neurobiology·2026

Same author

Functional neuroimaging biomarkers of impaired neurocognition after proton beam radiotherapy for brain tumors in pediatric patients: A prospective trial.

Neuro-oncology·2026

Same author

Inter- and intraspecific variation in theropod dinosaur dental microwear and its palaeoecological implications.

Anatomical record (Hoboken, N.J. : 2007)·2026

Same author

Beyond Oncogenes: Selectively Targeting Whole-Tumor Cell Growth Regulation.

Drug design, development and therapy·2026

Same author

Preneurosurgical Care for Patients With Trigeminal Neuralgia.

JAMA network open·2026

Same author

Radiation immunodynamics: association of baseline and longitudinal cytokine levels during radiotherapy in glioblastoma with survival.

Journal of neuro-oncology·2026

Search research articles

Related Experiment Video

Updated: May 5, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study.

David Wang¹, Natalie Hughes-Medlicott², Lilian Klingler³

¹Department of Anaesthesia, Waikato Hospital, Hamilton 3204, New Zealand.

|May 25, 2024

Summary

A new sensitive assay accurately measures unbound docetaxel in plasma. This supports the development of oral docetaxel plus encequidar (oDox+E) for improved cancer treatment.

Keywords:

clinical trial docetaxel unbound assay

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Experiment Videos

Last Updated: May 5, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Area of Science:

Pharmacology
Analytical Chemistry
Oncology

Background:

Docetaxel, a crucial taxane for solid tumors, is pharmacologically active in its unbound form.
Quantifying unbound docetaxel is vital for assessing drug toxicity and therapeutic effectiveness.
Current assay methods require improved sensitivity for unbound drug measurement.

Purpose of the Study:

To develop and validate a highly sensitive assay for quantifying unbound docetaxel.
To assess the utility of this assay in analyzing patient samples from an oral docetaxel plus encequidar (oDox+E) pharmacokinetic study.
To support the clinical development of an oral docetaxel formulation.

Main Methods:

Ultrafiltration coupled with high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).
Assay validation included long-term stability, precision, accuracy, and recovery assessments.
Analysis of patient plasma samples from a Phase I pharmacokinetic study.

Main Results:

The developed assay demonstrated excellent long-term stability (0.8–6.9% change over 131 days at -60 °C).
Assay precision and accuracy met FDA acceptance criteria, with an average recovery of 88%.
Successful quantification of unbound docetaxel in patient samples confirmed assay applicability.

Conclusions:

A validated, sensitive assay with a 0.084 ng/mL lower limit of quantification (LLOQ) was established for human plasma.
The assay's sensitivity enables pharmacokinetic modeling to compare oral docetaxel plus encequidar (oDox+E) with intravenous docetaxel.
The successful development of oDox+E offers a potential oral alternative to IV docetaxel, promising reduced costs, fewer side effects, and enhanced patient quality of life.